← Every applicant
Graviti Pharms FDA Approvals
11 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| GLIPIZIDENew drugMar 4, 2026TABLET, ORAL |
| LOSARTAN POTASSIUMNew drugSep 19, 2025TABLET, ORAL |
| LORAZEPAMNew drugJul 24, 2025TABLET, ORAL |
| SPIRONOLACTONENew drugJan 23, 2025TABLET, ORAL |
| PANTOPRAZOLE SODIUMNew drugJan 16, 2025TABLET, DELAYED RELEASE, ORAL |
| TRAZODONE HYDROCHLORIDENew drugAug 27, 2024TABLET, ORAL |
| FAMOTIDINENew drugMar 14, 2024TABLET, ORAL |
| HYDROXYZINE HYDROCHLORIDENew drugAug 17, 2023TABLET, ORAL |
| FUROSEMIDENew drugOct 17, 2022TABLET, ORAL |
| ESOMEPRAZOLE MAGNESIUMNew drugJun 24, 2022CAPSULE, DELAYED RELEASE, ORAL |
| ESOMEPRAZOLE MAGNESIUMNew drugMar 19, 2021CAPSULE, DELAYED REL PELLETS, ORAL |